-1.97%
-2.30%
4.56%
-16.99%
-36.60%
21.14%
-62.09%
AI Spotlight on PBYI
Company Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors.It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd.
The company was founded in 2010 and is headquartered in Los Angeles, California.
Market Data
| Last Price | 2.98 |
| Change Percentage | -1.97% |
| Open | 3.05 |
| Previous Close | 3.04 |
| Market Cap ( Millions) | 146 |
| Volume | 101510 |
| Year High | 7.73 |
| Year Low | 2.23 |
| M A 50 | 3.04 |
| M A 200 | 3.32 |
Financial Ratios
| FCF Yield | 23.02% |
| Dividend Yield | 0.00% |
| ROE | 41.50% |
| Debt / Equity | 121.50% |
| Net Debt / EBIDTA | 39.24% |
| Price To Book | 2.05 |
| Price Earnings Ratio | 6.28 |
| Price To FCF | 4.34 |
| Price To sales | 0.6 |
| EV / EBITDA | 3.4 |
News
- Jan -06 - Best Momentum Stocks to Buy for January 6th
- Jan -06 - Best Value Stocks to Buy for January 6th
- Jan -03 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Jan -01 - All You Need to Know About Puma Biotech (PBYI) Rating Upgrade to Strong Buy
- Dec -27 - Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why
- Dec -24 - Best Momentum Stocks to Buy for December 24th
- Dec -24 - New Strong Buy Stocks for December 24th
- Dec -24 - Best Value Stocks to Buy for December 24th
- Dec -23 - Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
- Dec -16 - Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
- Dec -04 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Nov -21 - PBYI Begins Phase II Study on Alisertib Combo in Breast Cancer
- Nov -08 - PBYI Beats Q3 Earnings & Revenue Estimates, Revises '24 View, Stock Up
- Nov -08 - Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript
- Nov -08 - Puma Biotech (PBYI) Q3 Earnings and Revenues Surpass Estimates
- Nov -05 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- Oct -29 - SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Puma Biotechnology, Inc. (NASDAQ: PBYI) and Encourages Investors to Contact the Firm
- Aug -02 - Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected
- Aug -02 - Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript
- Aug -01 - Puma Biotech (PBYI) Reports Q2 Loss, Tops Revenue Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Cancer Care Products
Expected Growth : 9.33 %
What the company do ?
Puma Biotechnology, Inc.'s cancer care products are a range of therapeutics, including Nerlynx, a tyrosine kinase inhibitor for HER2-positive breast cancer treatment.
Why we expect these perspectives ?
Puma Biotechnology's Cancer Care Products segment growth of 9.33% is driven by increasing adoption of Nerlynx, a HER2-positive breast cancer treatment, and expanding label indications. Strong sales momentum in the US and Europe, coupled with growing demand for targeted therapies, contribute to the segment's growth. Additionally, investments in R&D and strategic partnerships enhance the company's product pipeline and market presence.
Puma Biotechnology, Inc. Products
| Product Range | What is it ? |
|---|---|
| Nerlynx | Nerlynx (neratinib) is an oral tablet used to treat adult patients with early-stage HER2-positive breast cancer, following trastuzumab-based adjuvant therapy. |
Puma Biotechnology, Inc.'s Porter Forces
Threat Of Substitutes
Puma Biotechnology, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biotechnology industry.
Bargaining Power Of Customers
Puma Biotechnology, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.
Bargaining Power Of Suppliers
Puma Biotechnology, Inc. relies on a few key suppliers for raw materials and services, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.
Threat Of New Entrants
The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to compete with established companies like Puma Biotechnology, Inc.
Intensity Of Rivalry
The biotechnology industry is highly competitive, with many established companies competing for market share. Puma Biotechnology, Inc. faces intense competition from companies with similar products and technologies, which can lead to pricing pressure and reduced market share.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 66.15% |
| Debt Cost | 10.41% |
| Equity Weight | 33.85% |
| Equity Cost | 10.41% |
| WACC | 10.41% |
| Leverage | 195.46% |
Puma Biotechnology, Inc. : Quality Control
Puma Biotechnology, Inc. passed 4 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| ARDX | Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, … |
| AMLX | Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax … |
| ITOS | Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the … |
| APLT | Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for … |
| HRMY | Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Harmony Biosciences
A-Score
1-Year Total Return ->
🥈
Applied Therapeutics
A-Score
1-Year Total Return ->
🥉
Puma Biotechnology
A-Score
1-Year Total Return ->
4
Amylyx Pharmaceuticals
A-Score
1-Year Total Return ->
5
iTeos Therapeutics
A-Score
1-Year Total Return ->
6
